Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies

OBJECTIVE: To assess the recurrence interval and predictive significance of TP53 expression and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastomas treated with radiotherapy and combined chemotherapies, including temozolomide, lomustine, procarbazine and bevacizumab....

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Neurooncol
Hlavní autoři: Kurdi, Maher, Butt, Nadeem Shafique, Baeesa, Saleh, Alghamdi, Badrah, Maghrabi, Yazid, Bardeesi, Anas, Saeedi, Rothaina, Dallol, Ashraf, Mohamed, Fawaz, Bari, Mohammed O., Samkari, Alaa, Lary, Ahmed I., Alkhayyat, Shadi
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer US 2021
Témata:
Clinical Study
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8084807/
https://ncbi.nlm.nih.gov/pubmed/33661424
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-021-03723-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky